ESPR vs. RDUS, OMER, PAHC, CARA, CALT, PTGX, TARO, EWTX, ARDX, and GPCR
Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Radius Recycling (RDUS), Omeros (OMER), Phibro Animal Health (PAHC), Cara Therapeutics (CARA), Calliditas Therapeutics AB (publ) (CALT), Protagonist Therapeutics (PTGX), Taro Pharmaceutical Industries (TARO), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), and Structure Therapeutics (GPCR).
Radius Recycling (NASDAQ:RDUS) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap business services companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability.
78.1% of Radius Recycling shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 5.7% of Radius Recycling shares are owned by company insiders. Comparatively, 1.0% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Esperion Therapeutics had 1 more articles in the media than Radius Recycling. MarketBeat recorded 5 mentions for Esperion Therapeutics and 4 mentions for Radius Recycling. Esperion Therapeutics' average media sentiment score of 1.05 beat Radius Recycling's score of 0.73 indicating that Radius Recycling is being referred to more favorably in the media.
Radius Recycling has higher revenue and earnings than Esperion Therapeutics. Radius Recycling is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.
Radius Recycling has a net margin of -2.28% compared to Radius Recycling's net margin of -37.65%. Radius Recycling's return on equity of 0.00% beat Esperion Therapeutics' return on equity.
Esperion Therapeutics has a consensus target price of $9.33, indicating a potential upside of 332.10%. Given Radius Recycling's stronger consensus rating and higher probable upside, analysts plainly believe Esperion Therapeutics is more favorable than Radius Recycling.
Radius Recycling has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
Esperion Therapeutics received 258 more outperform votes than Radius Recycling when rated by MarketBeat users. Likewise, 69.92% of users gave Esperion Therapeutics an outperform vote while only 54.34% of users gave Radius Recycling an outperform vote.
Summary
Esperion Therapeutics beats Radius Recycling on 10 of the 18 factors compared between the two stocks.
Get Esperion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Esperion Therapeutics Competitors List
Related Companies and Tools
